Top Markets
#1 Purr Purr +58.55%
#2 Pons Pons +54.09%
#3 Smilek to the Bank Smilek to the Bank +50.56%
#4 Kinetiq Kinetiq +27.31%
#5 Non-Playable Coin Non-Playable Coin +26.21%
#6 ApeX ApeX +25.53%
#7 Pudgy Penguins Pudgy Penguins +21.06%
#8 OriginTrail OriginTrail +20.36%
#9 Morpho Morpho +20.09%
#10 Grass Grass +19.53%
Coin of the day
Purr Purr
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Talaris Therapeutics, Inc. Talaris Therapeutics, Inc.

Talaris Therapeutics, Inc.

TALS
Rang in Aktien #21258
Talaris Therapeutics, Inc. is a cell therapy company operating in the United... Talaris Therapeutics, Inc. is a cell therapy company operating in the United States, currently in its late clinical development stages. Its mission involves pioneering an allogeneic hematopoietic stem cell transplantation strategy designed to revolutionize treatment paradigms for solid organ transplantation, severe autoimmune conditions, and significant non-malignant blood, immune, and metabolic disorders. The company's flagship product, FCR001, is an innovative allogeneic cell therapy presently in Phase II clinical trials for patients undergoing living donor kidney transplantation. Beyond this, Talaris Therapeutics is actively advancing FCR002 for use in deceased donor kidney transplants, investigating FCR001 for individuals with a severe form of scleroderma, and exploring its applicability for a range of other serious non-malignant blood, immune, or metabolic conditions. Founded in 1988, the company maintains its headquarters in Louisville, Kentucky.
Aktienkurs
$2.72
Zuletzt synchronisiert: 2023-10-19
Marktkapitalisierung
$111.47M
Veränderung (1 Tag)
-0.73%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Talaris Therapeutics, Inc. (TALS)

Kategorie

Healthcare
P/S-Verhältnis für Talaris Therapeutics, Inc. (TALS)
P/S-Verhältnis zum 2026 TTM: 0
Laut den neuesten Finanzberichten und dem Aktienkurs von Talaris Therapeutics, Inc. beträgt das aktuelle Kurs-Umsatz-Verhältnis (TTM) 0. Am Ende des Jahres 2026 lag das P/S-Verhältnis bei 0.
P/S-Verlauf für Talaris Therapeutics, Inc. von 2026 bis 2026
P/S-Verhältnis zum Jahresende
Jahr P/S-Verhältnis ändert
Nicht genügend Daten für die angegebenen Daten.
P/S-Verhältnis für ähnliche Unternehmen oder Wettbewerber
Unternehmen P/S-Verhältnis P/S-Verhältnis-Differenz Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH